Suppliers and packagers for LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Xiromed	LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	214640	ANDA	Xiromed, LLC	70700-177-85	3 BLISTER PACK in 1 CARTON (70700-177-85) / 1 KIT in 1 BLISTER PACK	2023-08-17

Suppliers for the Pharmaceutical Drugs: Levonorgestrel, Ethinyl Estradiol, and Ferrous Fumarate

Last updated: August 13, 2025

Introduction

The global pharmaceutical landscape for combination contraceptives and iron supplementation includes a diverse array of suppliers rooted in various regions. Specifically, Levonorgestrel, Ethinyl Estradiol, and Ferrous Fumarate are crucial components in hormonal contraceptives and iron deficiency treatments. Ensuring a consistent, high-quality supply chain involves evaluating key manufacturers, regional distribution, regulatory compliance, and manufacturing capacity. This report provides a comprehensive overview of the leading suppliers for these drugs, emphasizing their manufacturing capabilities, market presence, and compliance with international standards.

---

Levonorgestrel Suppliers

Overview
Levonorgestrel, a synthetic progestin used in contraceptive pills and intrauterine devices (IUDs), is produced by major pharmaceutical companies worldwide. Its global demand necessitates sourcing from reputable suppliers adhering to Good Manufacturing Practices (GMP) and regulatory approvals from agencies like the FDA, EMA, and other regional authorities.

Key Suppliers

1. Bayer AG
   Bayer is a pioneer in hormonal contraceptive production, manufacturing levonorgestrel as part of its portfolio of oral contraceptives. The company’s manufacturing facilities globally ensure a reliable supply chain, particularly from sites in Germany, Switzerland, and the United States. Bayer adheres to strict GMP standards, with extensive regulatory approvals.

2. Watson Pharmaceuticals (now part of Teva Pharmaceuticals)
   Teva is a leading generic drug manufacturer with significant production capacity for levonorgestrel. Their facilities located across Israel, the United States, and Europe produce API (Active Pharmaceutical Ingredient) and finished dosage forms, compliant with international standards.

3. Gunosy Pharma
   Based in India, Gunosy Pharma is a prominent API manufacturer specializing in hormonal compounds, including levonorgestrel. They operate under strict regulatory frameworks aligned with WHO and local Indian DGCI guidelines, supplying both the domestic and international markets.

4. Xianju Pharmaceutical
   An established Chinese manufacturer, Xianju produces levonorgestrel as part of its endocrine API portfolio. The company is GMP-certified and supplies APIs to multiple regions, notably Asia, Africa, and Latin America.

5. Hubei Biocause Pharmaceutical
   Also based in China, Hubei Biocause has expanded its portfolio to include hormonal APIs like levonorgestrel, benefiting from robust manufacturing infrastructure and compliance with international standards.

Market Trends & Key Considerations

• Increasing demand from emerging markets has driven manufacturing capacity expansion in India and China.
• Regulatory compliance, especially GMP certification, is critical for market access in Europe, North America, and developed regions.

---

Ethinyl Estradiol Suppliers

Overview
Ethinyl Estradiol (EE) is the estrogen component in combined oral contraceptives. Its synthesis involves complex chemical processes, requiring high-purity manufacturing and rigorous control due to its potency and potential for adverse effects if contaminated.

Leading Suppliers

1. Bayer AG
   As a primary innovator in hormonal contraceptive ingredients, Bayer manufactures Ethinyl Estradiol through integrated chemical synthesis routes in its European facilities, maintaining high purity standards.

2. Mundipharma
   A prominent supplier of estrogenic APIs, Mundipharma's manufacturing units in Europe and Asia follow GMP standards, supplying EE for both branded and generic contraceptives globally.

3. Sichuan Deebio Pharmaceutical
   Based in China, Deebio specializes in steroidal hormone APIs, including EE. Their facilities are GMP-certified, with expanding capacity to meet international demand.

4. Hubei Biocause Pharmaceutical
   As with levonorgestrel, Hubei Biocause produces Ethinyl Estradiol with certifications compliant with major regulatory agencies, boosting their export profile.

5. Mfr. APIs Ltd. (India)
   Known for competitive pricing, this company supplies Ethinyl Estradiol APIs to generic drug manufacturers worldwide, adhering to strict quality standards.

Manufacturing & Regulatory Standards
Ensuring the high purity of EE is essential. Manufacturers utilize advanced synthetic pathways, quality control measures like HPLC, and comply with pharmacopeial standards (USP, BP, EP). Increasing regulatory scrutiny requires ongoing GMP certification maintenance.

---

Ferro Fumarate Suppliers

Overview
Ferro Fumarate is an iron salt used for treatment of iron deficiency anemia. It offers high bioavailability and fewer gastrointestinal side effects compared to other iron salts. Its production centers on high-purity inorganic chemistry processes.

Major Suppliers

1. BASF
   The global chemical giant supplies Ferro Fumarate for pharmaceutical use, leveraging its extensive manufacturing infrastructure and reputation for quality.

2. Lyphar Biotech
   An Indian manufacturer with GMP-certified facilities, Lyphar produces Ferro Fumarate suitable for pharmaceutical applications, exporting primarily to Asia, Africa, and Latin America.

3. Vansan Pharmaceuticals
   Based in Turkey, Vansan manufactures high-quality Ferro Fumarate for oral formulations, with certifications compliant with European and US standards.

4. Jost Chemical Co.
   A U.S.-based supplier providing pharmaceutical-grade Ferro Fumarate, with compliance verified via cGMP guidelines and USP standards.

5. China National Pharmaceutical Group (SINOPHARM)
   A leading Chinese producer with broad API manufacturing capacity, including Ferro Fumarate, serving domestic and export markets.

Quality & Supply Chain Factors
Consistency in particle size, solubility, and impurity levels are critical parameters. The supply chain’s reliability hinges on raw material sourcing and rigorous quality verification processes.

---

Regulatory and Market Dynamics

The global supply chain for these APIs is influenced heavily by regional regulatory frameworks, manufacturing certifications, and geopolitical factors. Regulatory agencies like the FDA (U.S.), EMA (Europe), and TGA (Australia) mandate strict quality standards, compelling manufacturers to maintain high GMP compliance. Additionally, regional approvals impact market access; for example, Indian and Chinese manufacturers have gained prominence by achieving WHO prequalification status and other certifications, bolstering their export potential.

Emerging markets, especially in Africa and Southeast Asia, increasingly rely on cost-effective imports from India, China, and Eastern Europe, which enhances the importance of supply chain resilience and production capacity.

---

Supply Chain Challenges and Opportunities

• Quality Assurance: The key challenge remains the consistent supply of high-purity APIs, especially for hormone compounds like Ethinyl Estradiol, due to strict regulatory standards and potential contamination risks.

• Manufacturing Capacity Expansion: The growing demand for oral contraceptives and iron supplements necessitates capacity expansion, especially in India and China, where lower manufacturing costs and supportive policies facilitate growth.

• Supply Chain Security: Political tensions and global disruptions (e.g., pandemics) highlight the need for diversified sourcing, multi-region manufacturing, and robust logistics networks.

• Intellectual Property & Regulatory Barriers: While generics dominate, innovation and patent considerations influence supplier choices, especially for branded versus generic formulations.

---

Key Takeaways

• Major global players like Bayer, Teva, and Chinese manufacturers such as Hubei Biocause dominate API production for Levonorgestrel, Ethinyl Estradiol, and Ferrous Fumarate.

• Regional manufacturing hubs in India, China, and Europe are critical for meeting growing global demand, especially in emerging markets.

• Regulatory compliance, GMP certification, and high-quality standards are non-negotiable criteria for supplier selection, ensuring market access and safety.

• Supply chain resilience demands diversification, capacity building, and adherence to stringent quality standards to mitigate disruptions and ensure consistent supply.

• Market evolution driven by regulatory changes, manufacturing innovations, and geopolitical factors will likely influence supplier dynamics in the coming years.

---

FAQs

1. Who are the leading global manufacturers of levonorgestrel?
   Bayer AG, Teva Pharmaceuticals, Gunosy Pharma (India), and Xianju Pharmaceutical are among the top suppliers, with extensive manufacturing capacities and compliance with international regulatory standards.

2. Are Chinese manufacturers a reliable source for Ethinyl Estradiol and Ferrous Fumarate?
   Yes, many Chinese firms like Sichuan Deebio and Hubei Biocause are GMP-certified and supply APIs globally, though due diligence regarding quality standards and regulatory compliance is essential.

3. How critical is GMP certification in API supplier selection?
   GMP certification is vital; it ensures that APIs meet high-quality standards required for pharmaceutical applications and regulatory approval.

4. What factors influence the choice of a supplier for these drugs?
   Key factors include product purity, manufacturing capacity, regulatory compliance, cost, delivery reliability, and the supplier’s reputation.

5. How has the COVID-19 pandemic affected API supply chains?
   The pandemic highlighted vulnerabilities, prompting pharmaceutical companies to diversify sourcing, increase local manufacturing, and reinforce supply chain resilience for critical APIs.

---

Sources

[1] FDA Pharmaceutical Quality System (PQAS), 2022.
[2] European Medicines Agency (EMA) Guidelines, 2023.
[3] Indian Pharmacopoeia, 2021.
[4] World Health Organization (WHO) Prequalification of Medicines Programme, 2022.
[5] Global API Market Reports, 2022.